2 research outputs found
Priority areas for cannabis and cannabinoid product research in South Africa
No abstract available
Priority areas for cannabis and cannabinoid product research in South Africa
CITATION: Augustine, T.N. et al. 2018. Priority areas for cannabis and cannabinoid product research in South Africa. African Journal of Primary Health Care & Family Medicine, 10(1):1-3, doi:10.4102/phcfm.v10i1.1711.The original publication is available at https://phcfm.org/index.php/phcfmThe legalisation of cannabis for medicinal use is a contentious space both politically and in the
medical community. In 2014, the Medical Innovation Bill introduced by Mario Oriani-Ambrosini
MP, aimed to shift the political and legal positions of cannabis as an illegal substance to one
available for research and medical use. To date, progress on this has been slow. Cannabis and
cannabinoid products are currently available for medicinal use in several countries, including the
Netherlands and 29 states in the United States. Locally, anecdotal reports suggest that many of
our patients with chronic medical conditions are using cannabis and cannabis-derived or
cannabinoid products for symptom alleviation.https://phcfm.org/index.php/phcfm/article/view/1711Publishers versio